Is FRMM or PRLD more profitable?

Prelude Therapeutics' return on equity of -118.24% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% Prelude Therapeutics N/A -118.24% -66.12%

Does the media refer more to FRMM or PRLD?

In the previous week, Forum Markets and Forum Markets both had 4 articles in the media. Prelude Therapeutics' average media sentiment score of 0.72 beat Forum Markets' score of 0.60 indicating that Prelude Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prelude Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer INDP or FRMM?

Forum Markets has a consensus target price of $10.00, indicating a potential upside of 93.80%. Given Forum Markets' stronger consensus rating and higher possible upside, analysts plainly believe Forum Markets is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Forum Markets 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is INDP or FRMM more profitable?

Forum Markets' return on equity of -242.09% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Indaptus Therapeutics N/A -1,030.07% -299.69% Forum Markets N/A -242.09% -135.46%

Does the media prefer INDP or FRMM?

In the previous week, Forum Markets had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 4 mentions for Forum Markets and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.95 beat Forum Markets' score of 0.60 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forum Markets 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, FRMM or CLLS?

Cellectis has higher revenue and earnings than Forum Markets. Cellectis is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forum Markets $6.55M 10.55 -$450.52M -$36.07 N/A Cellectis $79.59M 3.47 -$67.59M -$0.67 N/A

Is FRMM or CLLS more profitable?

Forum Markets has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% Cellectis -89.51% -80.66% -20.51%

Does the media refer more to FRMM or CLLS?

In the previous week, Forum Markets had 1 more articles in the media than Cellectis. MarketBeat recorded 4 mentions for Forum Markets and 3 mentions for Cellectis. Cellectis' average media sentiment score of 0.94 beat Forum Markets' score of 0.60 indicating that Cellectis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FRMM or FHTX?

In the previous week, Forum Markets had 3 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 4 mentions for Forum Markets and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.26 beat Forum Markets' score of 0.60 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate AMRN or FRMM?

Forum Markets has a consensus target price of $10.00, suggesting a potential upside of 93.80%. Given Forum Markets' higher possible upside, analysts plainly believe Forum Markets is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Forum Markets 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, AMRN or FRMM?

Amarin has higher revenue and earnings than Forum Markets. Amarin is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $213.65M 1.40 -$38.80M -$0.99 N/A Forum Markets $6.55M 10.55 -$450.52M -$36.07 N/A

Is AMRN or FRMM more profitable?

Forum Markets has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Amarin -14.56% -0.20% -0.14% Forum Markets N/A -242.09% -135.46%

Does the media prefer AMRN or FRMM?

In the previous week, Amarin had 7 more articles in the media than Forum Markets. MarketBeat recorded 11 mentions for Amarin and 4 mentions for Forum Markets. Amarin's average media sentiment score of 0.70 beat Forum Markets' score of 0.60 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Forum Markets 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Forum Markets (FRMM) Competitors

$5.16 -0.21 (-3.91%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$5.35 +0.19 (+3.76%)

As of 07/31/2026 07:52 PM Eastern

Compare

FRMM vs. PRLD, INDP, CLLS, FHTX, and AMRN

Should you buy Forum Markets stock or one of its competitors? MarketBeat compares Forum Markets with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Forum Markets include Prelude Therapeutics (PRLD), Indaptus Therapeutics (INDP), Cellectis (CLLS), Foghorn Therapeutics (FHTX), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry.

How does Forum Markets compare to Prelude Therapeutics?

Forum Markets (NASDAQ:FRMM) and Prelude Therapeutics (NASDAQ:PRLD) are related small-cap companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

In the previous week, Forum Markets and Forum Markets both had 4 articles in the media. Prelude Therapeutics' average media sentiment score of 0.72 beat Forum Markets' score of 0.60 indicating that Prelude Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prelude Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4.1% of Forum Markets shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 25.2% of Forum Markets shares are held by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Forum Markets has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Forum Markets currently has a consensus target price of $10.00, indicating a potential upside of 93.80%. Prelude Therapeutics has a consensus target price of $7.67, indicating a potential upside of 66.67%. Given Forum Markets' stronger consensus rating and higher possible upside, equities analysts plainly believe Forum Markets is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Prelude Therapeutics has higher revenue and earnings than Forum Markets. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	10.55	-$450.52M	-$36.07	N/A
Prelude Therapeutics	$12.14M	30.18	-$99.50M	-$1.00	N/A

Prelude Therapeutics' return on equity of -118.24% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Prelude Therapeutics	N/A	-118.24%	-66.12%

Summary

Prelude Therapeutics beats Forum Markets on 10 of the 15 factors compared between the two stocks.

How does Forum Markets compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Forum Markets (NASDAQ:FRMM) are related small-cap companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

In the previous week, Forum Markets had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 4 mentions for Forum Markets and 1 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.95 beat Forum Markets' score of 0.60 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indaptus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forum Markets	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of Forum Markets shares are owned by institutional investors. 9.9% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 25.2% of Forum Markets shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Indaptus Therapeutics has higher earnings, but lower revenue than Forum Markets. Forum Markets is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A
Forum Markets	$6.55M	10.55	-$450.52M	-$36.07	N/A

Indaptus Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Forum Markets has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Forum Markets' return on equity of -242.09% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%
Forum Markets	N/A	-242.09%	-135.46%

Forum Markets has a consensus target price of $10.00, indicating a potential upside of 93.80%. Given Forum Markets' stronger consensus rating and higher possible upside, analysts plainly believe Forum Markets is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Forum Markets beats Indaptus Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Forum Markets compare to Cellectis?

Forum Markets (NASDAQ:FRMM) and Cellectis (NASDAQ:CLLS) are related small-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Forum Markets has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.88, suggesting that its share price is 188% more volatile than the broader market.

4.1% of Forum Markets shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 25.2% of Forum Markets shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cellectis has higher revenue and earnings than Forum Markets. Cellectis is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	10.55	-$450.52M	-$36.07	N/A
Cellectis	$79.59M	3.47	-$67.59M	-$0.67	N/A

Forum Markets presently has a consensus target price of $10.00, suggesting a potential upside of 93.80%. Cellectis has a consensus target price of $7.00, suggesting a potential upside of 154.55%. Given Cellectis' stronger consensus rating and higher probable upside, analysts clearly believe Cellectis is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Forum Markets has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Cellectis	-89.51%	-80.66%	-20.51%

In the previous week, Forum Markets had 1 more articles in the media than Cellectis. MarketBeat recorded 4 mentions for Forum Markets and 3 mentions for Cellectis. Cellectis' average media sentiment score of 0.94 beat Forum Markets' score of 0.60 indicating that Cellectis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cellectis beats Forum Markets on 11 of the 16 factors compared between the two stocks.

How does Forum Markets compare to Foghorn Therapeutics?

Forum Markets (NASDAQ:FRMM) and Foghorn Therapeutics (NASDAQ:FHTX) are related small-cap companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

4.1% of Forum Markets shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 25.2% of Forum Markets shares are held by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Forum Markets currently has a consensus target price of $10.00, suggesting a potential upside of 93.80%. Foghorn Therapeutics has a consensus target price of $11.43, suggesting a potential upside of 152.29%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Foghorn Therapeutics has higher revenue and earnings than Forum Markets. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	10.55	-$450.52M	-$36.07	N/A
Foghorn Therapeutics	$30.91M	8.60	-$74.28M	-$1.16	N/A

Forum Markets has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.86, meaning that its stock price is 186% more volatile than the broader market.

In the previous week, Forum Markets had 3 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 4 mentions for Forum Markets and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.26 beat Forum Markets' score of 0.60 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Forum Markets has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Summary

Foghorn Therapeutics beats Forum Markets on 11 of the 16 factors compared between the two stocks.

How does Forum Markets compare to Amarin?

Amarin (NASDAQ:AMRN) and Forum Markets (NASDAQ:FRMM) are related small-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Amarin has higher revenue and earnings than Forum Markets. Amarin is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.40	-$38.80M	-$0.99	N/A
Forum Markets	$6.55M	10.55	-$450.52M	-$36.07	N/A

Amarin has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Forum Markets has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

22.3% of Amarin shares are owned by institutional investors. Comparatively, 4.1% of Forum Markets shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 25.2% of Forum Markets shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Forum Markets has a consensus target price of $10.00, suggesting a potential upside of 93.80%. Given Forum Markets' higher possible upside, analysts plainly believe Forum Markets is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Amarin had 7 more articles in the media than Forum Markets. MarketBeat recorded 11 mentions for Amarin and 4 mentions for Forum Markets. Amarin's average media sentiment score of 0.70 beat Forum Markets' score of 0.60 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Forum Markets	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Forum Markets has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Forum Markets	N/A	-242.09%	-135.46%

Summary

Amarin beats Forum Markets on 8 of the 15 factors compared between the two stocks.

Get Forum Markets News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FRMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FRMM vs. The Competition

Export

Metric	Forum Markets	Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$71.91M	$2.87B	$10.57B	$12.30B
Dividend Yield	N/A	13.91%	120.65%	9.45%
P/E Ratio	-0.14	13.45	27.47	24.67
Price / Sales	10.55	4,849.35	944.35	110.49
Price / Cash	N/A	124.43	24.14	59.62
Price / Book	0.41	17.44	4.47	5.90
Net Income	-$450.52M	-$13.44M	$609.30M	$336.16M
7 Day Performance	-9.95%	0.17%	0.24%	0.08%
1 Month Performance	-7.36%	-0.68%	-2.64%	-5.67%
1 Year Performance	N/A	10.33%	12.05%	18.82%

Forum Markets Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FRMM Forum Markets	3.7358 of 5 stars	$5.16 -3.9%	$10.00 +93.8%	N/A	$71.91M	$6.55M	N/A	7	Insider Trade
PRLD Prelude Therapeutics	2.1511 of 5 stars	$3.83 -2.5%	$7.67 +100.2%	+489.8%	$305.04M	$12.14M	N/A	120	News Coverage Analyst Forecast
INDP Indaptus Therapeutics	0.547 of 5 stars	$2.61 -5.8%	N/A	-84.2%	$295.56M	N/A	N/A	6	News Coverage Short Interest Increase
CLLS Cellectis	2.3755 of 5 stars	$2.84 +2.5%	$7.00 +146.5%	+9.6%	$284.96M	$79.59M	N/A	290	News Coverage Upcoming Earnings
FHTX Foghorn Therapeutics	3.297 of 5 stars	$4.85 -4.3%	$11.43 +135.6%	-13.7%	$284.76M	$30.91M	N/A	120	News Coverage Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FRMM) was last updated on 8/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Forum Markets (FRMM) Competitors

FRMM vs. PRLD, INDP, CLLS, FHTX, and AMRN

How does Forum Markets compare to Prelude Therapeutics?

Summary

How does Forum Markets compare to Indaptus Therapeutics?

Summary

How does Forum Markets compare to Cellectis?

Summary

How does Forum Markets compare to Foghorn Therapeutics?

Summary

How does Forum Markets compare to Amarin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRMM vs. The Competition

Forum Markets Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Forum Markets (FRMM) Competitors

FRMM vs. PRLD, INDP, CLLS, FHTX, and AMRN

How does Forum Markets compare to Prelude Therapeutics?

Does the media refer more to FRMM or PRLD?

Do insiders & institutionals believe in FRMM or PRLD?

Which has more risk & volatility, FRMM or PRLD?

Do analysts recommend FRMM or PRLD?

Which has stronger earnings & valuation, FRMM or PRLD?

Is FRMM or PRLD more profitable?

Summary

How does Forum Markets compare to Indaptus Therapeutics?

Does the media prefer INDP or FRMM?

Do insiders & institutionals have more ownership in INDP or FRMM?

Which has higher earnings and valuation, INDP or FRMM?

Which has more volatility and risk, INDP or FRMM?

Is INDP or FRMM more profitable?

Do analysts prefer INDP or FRMM?

Summary

How does Forum Markets compare to Cellectis?

Which has more volatility & risk, FRMM or CLLS?

Do institutionals & insiders have more ownership in FRMM or CLLS?

Which has higher valuation & earnings, FRMM or CLLS?

Do analysts prefer FRMM or CLLS?

Is FRMM or CLLS more profitable?

Does the media refer more to FRMM or CLLS?

Summary

How does Forum Markets compare to Foghorn Therapeutics?

Do insiders and institutionals have more ownership in FRMM or FHTX?

Do analysts recommend FRMM or FHTX?

Which has preferable valuation & earnings, FRMM or FHTX?

Which has more risk and volatility, FRMM or FHTX?

Does the media refer more to FRMM or FHTX?

Is FRMM or FHTX more profitable?

Summary

How does Forum Markets compare to Amarin?

Which has higher valuation & earnings, AMRN or FRMM?

Which has more risk and volatility, AMRN or FRMM?

Do institutionals and insiders hold more shares of AMRN or FRMM?

Do analysts rate AMRN or FRMM?

Does the media prefer AMRN or FRMM?

Is AMRN or FRMM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRMM vs. The Competition

Forum Markets Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools